Aouizerate P, Dumé L, Bouleau D, Duvaldestin P, Astier A
Service de Pharmacie du Centre Hospitalier de Meaux, France.
Therapie. 1998 Nov-Dec;53(6):543-51.
PaMo 2.0, a type of software, includes a pharmacokinetic model for propofol in the adult. It allows both administration and monitoring of propofol target-controlled infusions. In order to evaluate PaMo 2.0, a prospective clinical trial compared, at defined infusion times, predicted and measured plasma propofol concentrations, in 28 patients programmed for hip-replacement surgery. A propofol plasma determination technique had first been validated, including high performance liquid chromatography with fluorescence detection. A statistical analysis based on correlation (r = 0.73), inaccuracy = 29.18 per cent, bias = 11.67 per cent, wobble = 19.15 per cent, and divergence = -0.06 per cent/min calculation, related to this system, has been carried out. PaMo 2.0 under-estimated plasma propofol concentrations. The convergence between predicted and measured propofol concentrations was good and not modified in respect of infusion time. This infusion system is suitable for propofol administration, but the integration of Bayesian pharmacokinetic models would greatly improve propofol plasma concentration estimation and regimen adaptation to each patient.
PaMo 2.0是一款软件，包含成人丙泊酚的药代动力学模型。它可用于丙泊酚靶控输注的给药和监测。为评估PaMo 2.0，一项前瞻性临床试验比较了28例计划进行髋关节置换手术患者在规定输注时间下丙泊酚的预测血浆浓度和实测血浆浓度。首先验证了一种丙泊酚血浆测定技术，包括荧光检测高效液相色谱法。基于相关性（r = 0.73）、不准确度 = 29.18%、偏差 = 11.67%、摆动 = 19.15%以及与该系统相关的发散 = -0.06%/分钟计算进行了统计分析。PaMo 2.0低估了丙泊酚血浆浓度。预测和实测丙泊酚浓度之间的收敛性良好，且不受输注时间影响。该输注系统适用于丙泊酚给药，但贝叶斯药代动力学模型的整合将极大地改善丙泊酚血浆浓度估计以及根据每位患者调整给药方案。
